No new biosimilars of ‘Avastin (Roche, bevacizumab)' are being introduced to the market after Samsung Bioepis’s biosimilar. The Avastin biosimilar market is estimated to have a ₩120 billion market in Korea. In terms of approvals, Pfizer Korea and Alvogen Korea had also received approval for their biosimilars after
Samsung Bioepis, but only Samsung Bioepis received reimbursement approval for its biosimilar in September last year.

The industry analysis is that the supply amount and results of patent challenges have risen as a variable, delaying reimbursement and release of the other biosimilars.

According to industry sources on the 13th, Alvogen Korea withdrew its r